These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18827195)

  • 41. Suppression of TLR2-induced IL-12, reactive oxygen species, and inducible nitric oxide synthase expression by Mycobacterium tuberculosis antigens expressed inside macrophages during the course of infection.
    Gupta D; Sharma S; Singhal J; Satsangi AT; Antony C; Natarajan K
    J Immunol; 2010 May; 184(10):5444-55. PubMed ID: 20385877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Major histocompatibility complex restriction of T-cell suppression of immune response to mycobacteria.
    Shroff KE; Sainis KB; Sengupta SR; Kamat RS
    Int J Lepr Other Mycobact Dis; 1991 Mar; 59(1):49-57. PubMed ID: 1827647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production.
    Rodríguez-Güell E; Agustí G; Corominas M; Cardona PJ; Casals I; Parella T; Sempere MA; Luquin M; Julián E
    Antonie Van Leeuwenhoek; 2006 Jul; 90(1):93-108. PubMed ID: 16652204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunotherapy for MDR-TB (multi-drug resistant tuberculosis)--its feasibility].
    Tsuyuguchi I
    Kekkaku; 1999 Jun; 74(6):479-91. PubMed ID: 10423959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa.
    Onyebujoh PC; Abdulmumini T; Robinson S; Rook GA; Stanford JL
    Respir Med; 1995 Mar; 89(3):199-207. PubMed ID: 7746913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.
    Dlugovitzky D; Fiorenza G; Farroni M; Bogue C; Stanford C; Stanford J
    Respir Med; 2006 Jun; 100(6):1079-87. PubMed ID: 16278080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis.
    Johnson JL; Nunn AJ; Fourie PB; Ormerod LP; Mugerwa RD; Mwinga A; Chintu C; Ngwira B; Onyebujoh P; Zumla A
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1348-54. PubMed ID: 15581204
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment with Mycobacterium vaccae ameliorates airway histopathology in a murine model of asthma.
    Yazi D; Akkoc T; Yesil O; Ozdemir C; Aydoğan M; Koksalan K; Bahceciler NN; Barlan IB
    Allergy Asthma Proc; 2008; 29(1):67-73. PubMed ID: 18302841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model.
    Dormans J; Burger M; Aguilar D; Hernandez-Pando R; Kremer K; Roholl P; Arend SM; van Soolingen D
    Clin Exp Immunol; 2004 Sep; 137(3):460-8. PubMed ID: 15320894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.
    Yang XY; Chen QF; Li YP; Wu SM
    PLoS One; 2011; 6(9):e23826. PubMed ID: 21909406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae.
    Bahr GM; Shaaban MA; Gabriel M; al-Shimali B; Siddiqui Z; Chugh TD; Denath FM; Shahin A; Behbehani K; Chedid L
    Tubercle; 1990 Dec; 71(4):259-66. PubMed ID: 2267679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mycobacterium vaccae immunotherapy for treating tuberculosis.
    de B; Garner P
    Cochrane Database Syst Rev; 2001; (1):CD001166. PubMed ID: 11279709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and characterization of a novel anti-inflammatory lipid isolated from Mycobacterium vaccae, a soil-derived bacterium with immunoregulatory and stress resilience properties.
    Smith DG; Martinelli R; Besra GS; Illarionov PA; Szatmari I; Brazda P; Allen MA; Xu W; Wang X; Nagy L; Dowell RD; Rook GAW; Rosa Brunet L; Lowry CA
    Psychopharmacology (Berl); 2019 May; 236(5):1653-1670. PubMed ID: 31119329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mycobacterium vaccae immunotherapy for treating tuberculosis.
    de Bruyn G; Garner P
    Cochrane Database Syst Rev; 2003; (1):CD001166. PubMed ID: 12535403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.
    Roy E; Stavropoulos E; Brennan J; Coade S; Grigorieva E; Walker B; Dagg B; Tascon RE; Lowrie DB; Colston MJ; Jolles S
    Infect Immun; 2005 Sep; 73(9):6101-9. PubMed ID: 16113331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.
    Hernández-Pando R; Orozco-Esteves H; Maldonado HA; Aguilar-León D; Vilchis-Landeros MM; Mata-Espinosa DA; Mendoza V; López-Casillas F
    Clin Exp Immunol; 2006 May; 144(2):264-72. PubMed ID: 16634800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of IL-17A on the immune response to pulmonary tuberculosis induced by high- and low-virulence strains of Mycobacterium bovis.
    Rodríguez-Míguez Y; Lozano-Ordaz V; Ortiz-Cabrera AE; Barrios-Payan J; Mata-Espinosa D; Huerta-Yepez S; Baay-Guzman G; Hernández-Pando R
    PLoS One; 2024; 19(7):e0307307. PubMed ID: 39024223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Mycobacterium vaccae immunization on lung histopathology in a murine model of chronic asthma.
    Ozdemir C; Akkoc T; Bahceciler NN; Kucukercan D; Barlan IB; Basaran MM
    Clin Exp Allergy; 2003 Feb; 33(2):266-70. PubMed ID: 12580921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection.
    Hernandez-Pando R; Pavön L; Arriaga K; Orozco H; Madrid-Marina V; Rook G
    Infect Immun; 1997 Aug; 65(8):3317-27. PubMed ID: 9234793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes.
    Gong WP; Liang Y; Ling YB; Zhang JX; Yang YR; Wang L; Wang J; Shi YC; Wu XQ
    Mil Med Res; 2020 Jun; 7(1):25. PubMed ID: 32493477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.